🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

UroGen Pharma Ltd.

URGN Healthcare
$43.2 $-0.05 (-0.12%)
Market Cap: $2.11 B
Gurus Holding
5
Popularity Rank
#2105
% of Shares Held
8.28%
Net Activity (Q2 2026)
+$58.4 M

Guru Ownership Trend

Guru Analysis for UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q2 2026, a total of 5 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $174.8 M.

Top institutional holders include Jefferies Group and Steven Cohen.

Institutional sentiment is currently Strongly Bullish. This is evidenced by a $58.4 M net inflow during the quarter.

Recent activity highlights Steven Cohen who opened a new position. Conversely, Catherine Wood reduced exposure by 12.2%.

Key Holders

Top 5 by Value

Recent Activity Breakdown (Q2 2026)

+$58.92 M
Total Buy Value
New Buys 2
Additions 1
-$516,561.54
Total Sell Value
Reductions 1
Sold Out 0

Guru Consensus (Q2 2026)

Based on recent activity
Net Sellers
1
Net Buyers
3

FAQs for UroGen Pharma Ltd. (URGN)

Major holders include Jefferies Group ($80.95 M), Steven Cohen ($56.14 M), Cliff Asness ($5.49 M). According to the latest reported data, 5 tracked investment managers collectively hold approximately 4.05 M shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $58.4 M, with 3 managers increasing positions and 1 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 0 fully exited URGN. The total reported sell value was $516,561.54.

Yes, 2 managers opened new positions in URGN, and 1 increased their existing holdings. The total reported buy value was $58.92 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.53% 2,199,652 $80.95 M Q2 2026
0.06% New Buy 1,525,549 $56.14 M Q2 2026
0.00% Add 3.6% 149,228 $5.49 M Q2 2026
0.02% Reduce -12.2% 101,508 $3.74 M Q2 2026
0.00% New Buy 70,300 $2.59 M Q2 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form